公开(公告)号：US20240141293A1

公开(公告)日：2024-05-02

申请号：US18540309

申请日：2023-12-14

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: C12N5/0783 ,  A61K35/17 ,  C12N9/22 ,  C12N15/90

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C12N9/22 ,  C12N15/907 ,  C12N2510/00 ,  C12N2750/14143 ,  C12N2830/008

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20230287454A1

公开(公告)日：2023-09-14

申请号：US18303080

申请日：2023-04-19

Applicant: CELLECTIS

Inventor： Jean-Pierre CABANIOLS ,  Jean-Charles EPINAT ,  Philippe DUCHATEAU

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/86 ,  C12N5/0636 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/902 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US20230138915A1

公开(公告)日：2023-05-04

申请号：US16340412

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Brian BUSSER ,  Alexandre JUILLERAT ,  Anne-Sophie GAUTRON ,  Laurent POIROT

IPC: C12N15/90 ,  C12N15/11 ,  C12N9/22 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention relates to the fields of immunotherapy, molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a TALEN-modified human primary cell comprising in its genome, a modified human T cell receptor alpha gene with an insertion comprising at least, from 5′ to 3′, a polynucleotide encoding a self-cleaving peptide, a chimeric antigen receptor, wherein the cell has undetectable cell-surface expression of the endogenous alpha beta T cell receptor as compared to a TCR positive control cell and expresses a receptor to target a pathological cell, use of said cell for treating a disease, including cancer. The invention further relates to methods for producing such a TALEN-modified cell, and to means for detecting such an engineered human primary cell or other genetically modified human primary cell obtained using alternative and/or additional rare cutting endonucleases.

公开(公告)号：US20230087122A1

公开(公告)日：2023-03-23

申请号：US17817877

申请日：2022-08-05

Applicant: CELLECTIS

Inventor： Jean-Pierre CABANIOLS ,  Jean-Charles EPINAT ,  Philippe DUCHATEAU

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US20220233588A1

公开(公告)日：2022-07-28

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David SOURDIVE ,  Aymeric DUCLERT ,  Mathieu SIMON ,  Philippe DUCHATEAU ,  Alan Marc WILLIAMS ,  Laurent POIROT

IPC: A61K35/17 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US20200277625A1

公开(公告)日：2020-09-03

申请号：US16793896

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  A61K35/17 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20200224163A1

公开(公告)日：2020-07-16

申请号：US16340222

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: C12N5/0783 ,  A61K35/17 ,  C12N15/90 ,  C12N9/22

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20200208174A1

公开(公告)日：2020-07-02

申请号：US16314697

申请日：2017-06-30

Applicant: CELLECTIS

Inventor： Jean-Pierre CABANIOLS ,  Jean-Charles EPINAT ,  Philippe DUCHATEAU

IPC: C12N15/86 ,  C12N13/00 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/113 ,  C12N15/90

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient,for their subsequent use in therapeutic treatments.

公开(公告)号：US20180171298A1

公开(公告)日：2018-06-21

申请号：US15578946

申请日：2016-06-30

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  Jean-Pierre CABANIOLS ,  Julien VALTON

IPC: C12N5/0783 ,  C12N15/63 ,  A61K35/17 ,  A61K45/06 ,  C12N9/22 ,  C07K14/47 ,  C07K14/725 ,  C12N9/12

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K45/06 ,  A61K2039/515 ,  A61K2039/572 ,  C07K14/4703 ,  C07K14/7051 ,  C12N9/12 ,  C12N9/22 ,  C12N15/63 ,  C12N2510/00

Abstract: The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.

公开(公告)号：US20180051089A1

公开(公告)日：2018-02-22

申请号：US15546623

申请日：2016-01-25

Applicant: Cellectis

Inventor： Roman GALETTO ,  Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON ,  Mathieu SIMON

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.